Search results
Results from the WOW.Com Content Network
CHICAGO, June 27, 2024 — A workgroup convened by the Alzheimer’s Association has published revised criteria for the diagnosis and staging of Alzheimer’s disease that are based on the biology of the disease and reflect recent advancements in Alzheimer’s research, diagnostics and treatment.
Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.
PMCID: PMC11350039. DOI: 10.1002/alz.13859. Abstract. The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD).
We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms.
The 2024 criteria provides an outline for the diagnosis and staging of Alzheimer's disease. Several core principles emerged from these efforts, including: Alzheimer’s disease should be defined biologically, not based on a clinical syndrome (s).
From upcoming drug approval decisions to late-stage clinical trial readouts—this year promises many developments for Alzheimer’s and dementia treatments coming down the pipeline. In 2024, there are 171 ongoing studies and 134 drugs being tested in clinical trials .
The current treatment guidelines for AD as established by the American Psychiatric Association (APA), the EAN, and the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia are listed in (Table 3) .
This study presents a systematic literature review (SLR) of current clinical practice guidelines for screening, diagnosis, monitoring and treatment recommendations for the AD continuum with a focus on identifying key areas for future advancements.
The Food and Drug Administration (FDA) recently granted full approval to a new Alzheimer’s treatment called lecanemab, which has been shown to moderately slow cognitive and functional decline in early-stage cases of the disease.
In January 2023, the US Food and Drug Administration (FDA) approved lecanemab — an antibody medication that decreases β-amyloid protein build-up in the brain — as a treatment for Alzheimer’s...